An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells

Mohammad Haque; Xiaofang Xiong; Fengyang Lei; Jugal Kishore Das; Jianxun Song

doi:10.1016/j.xpro.2020.100264

An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells

STAR Protoc. 2021 Jan 12;2(1):100264. doi: 10.1016/j.xpro.2020.100264. eCollection 2021 Mar 19.

Authors

Mohammad Haque¹, Xiaofang Xiong¹, Fengyang Lei², Jugal Kishore Das¹, Jianxun Song¹

Affiliations

¹ Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, MREB II, Room 3344, 8447 Riverside Pkwy, Bryan, TX 77807, USA.
² Department of Ophthalmology, Harvard Medical School, Boston, MA 02215, USA.

Abstract

In T cell-based cancer immunotherapy, tumor antigen (Ag)-specific CD8⁺ cytotoxic T lymphocytes (CTLs) can specifically target tumor Ags on malignant cells. This promising approach drove us to adopt this strategy of T cell transfer (ACT)-based immunotherapy for chronic viral infections. Here, we describe the generation of hepatitis B virus (HBV) Ag-specific CTLs from induced pluripotent stem cells (iPSCs), i.e., iPSC-CTLs. Ag-specific iPSC-CTLs can target HBV Ag⁺ cells and infiltrate into the liver to suppress HBV replication in a murine model. For complete details on the use and execution of this protocol, please refer to Haque et al. (2020).

Keywords: Immunology; Stem Cells.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Animals
Hepatitis B / immunology
Hepatitis B / therapy
Hepatitis B Antigens / immunology*
Hepatitis B virus / immunology*
Humans
Immunotherapy, Adoptive
Induced Pluripotent Stem Cells / immunology*
Mice
T-Lymphocytes, Cytotoxic / immunology*

Substances

Hepatitis B Antigens

Abstract

Publication types

MeSH terms

Substances

Grants and funding